{
  "chapters": [
    {
      "number": 1,
      "title": "Intro",
      "durationSec": 32,
      "positionSec": 0
    },
    {
      "number": 2,
      "title": "Begrüßung",
      "durationSec": 46,
      "positionSec": 32
    },
    {
      "number": 3,
      "title": "Lars Fischer",
      "durationSec": 110,
      "positionSec": 79
    },
    {
      "number": 4,
      "title": "Faszination für Viren und Seuchen",
      "durationSec": 195,
      "positionSec": 189
    },
    {
      "number": 5,
      "title": "Stand der Dinge bei SARS-Cov-2",
      "durationSec": 799,
      "positionSec": 384
    },
    {
      "number": 6,
      "title": "Der PCR-Test",
      "durationSec": 115,
      "positionSec": 1184
    },
    {
      "number": 7,
      "title": "Inaktivierte Viren",
      "durationSec": 754,
      "positionSec": 1299
    },
    {
      "number": 8,
      "title": "DNA/RNA und Vektorimpfstoffe",
      "durationSec": 625,
      "positionSec": 2053
    },
    {
      "number": 9,
      "title": "Lebendimpfstoffe",
      "durationSec": 137,
      "positionSec": 2679
    },
    {
      "number": 10,
      "title": "Virusähnliche Partikel",
      "durationSec": 143,
      "positionSec": 2817
    },
    {
      "number": 11,
      "title": "Welche Impfstoffe können helfen?",
      "durationSec": 456,
      "positionSec": 2960
    },
    {
      "number": 12,
      "title": "Mögliche negative Auswirkungen",
      "durationSec": 167,
      "positionSec": 3417
    },
    {
      "number": 13,
      "title": "Impfstoffentwicklung in Deutschland",
      "durationSec": 320,
      "positionSec": 3584
    },
    {
      "number": 14,
      "title": "Ausblick",
      "durationSec": 379,
      "positionSec": 3904
    },
    {
      "number": 15,
      "title": "Mutation und Behandlungsoptionen",
      "durationSec": 386,
      "positionSec": 4284
    },
    {
      "number": 16,
      "title": "Ausklang",
      "durationSec": 117,
      "positionSec": 4670
    }
  ]
}